Human EGFR Stable Cell Line-Ba/F3

Name: Human EGFR Stable Cell Line-Ba/F3
SKU: CSC-RO0126
Availability: InStock

For research use only. Not intended for any clinical use.

Cat. No. : CSC-RO0126

Host Cell : Ba/F3 Size : >1x10⁶ frozen cells/vial

Inquire for Price

Cell Line Information

Cell Culture Information

Safety and Packaging

Gene Information

Documents

Cat. No.	CSC-RO0126
Description	Ba/F3-EGFR cell line is a stably transfected cell line which expresses human epidermal growth factor receptor (EGFR).
Target Gene	EGFR
Gene Species	Homo sapiens (Human)
Host Cell	Ba/F3
Host Cell Species	Mus musculus (Mouse)
Applications	Drug screening and biological assays
Biosafety Level	2
Size	>1x10^6 frozen cells/vial, 1 mL
Stability	Stable in culture over a minimum of 10 passages
Quality Control	Negative for bacteria, yeast, fungi and mycoplasma.
Growth Conditions	37 °C, 5% CO₂
Shipping	Dry ice

Thawing & Subculturing Instructions	1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap. 2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely. 3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min. 4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker). 5. Incubate the culture at 37°C with 5% CO2. 6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL.
Freeze Medium	Frozen with 70% medium, 20% FBS, 10% DMSO
Growth Properties	Suspension, round
Freezing Instructions	Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker). 1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium. 6. Aliquot 1 ml of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage.

Mycoplasma	Negative
Format	One frozen vial containing millions of cells
Storage	Liquid nitrogen
Safety Considerations	The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach.
Ship	Dry ice

Gene Name	EGFR epidermal growth factor receptor [ Homo sapiens ]
Gene Symbol	EGFR
Synonyms	ERBB; HER1; mENA; ERBB1; PIG61
Gene Description	epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)
GeneID	1956
Uni ProtID	P00533
mRNA Refseq	NM_005228.3
Protein Refseq	NP_005219.2
Chromosome Location	7p12
Function	ATP binding; MAP kinase kinase kinase activity; actin filament binding; double-stranded DNA binding; enzyme binding; epidermal growth factor-activated receptor activity; epidermal growth factor-activated receptor activity; identical protein binding; contributes_to nitric-oxide synthase regulator activity; protein binding; protein heterodimerization activity; protein phosphatase binding; protein tyrosine kinase activity; protein tyrosine kinase activity; protein tyrosine kinase activity; receptor signaling protein tyrosine kinase activity; transmembrane receptor protein tyrosine kinase activity; transmembrane signaling receptor activity;
Pathway	Adaptive Immune System, organism-specific biosystem; Adherens junction, organism-specific biosystem; Adherens junction, conserved biosystem; Alpha6-Beta4 Integrin Signaling Pathway, organism-specific biosystem; Androgen Receptor Signaling Pathway, organism-specific biosystem; Arf6 signaling events, organism-specific biosystem; Axon guidance, organism-specific biosystem;
MIM	131550

CSC-RO0126-Human EGFR Stable Cell Line-Ba/F3-Datasheet

Quick Inquiry

Background

Case Study

Applications

Q & A

Customer Reviews

The EGFR (Epidermal Growth Factor Receptor) gene is a crucial element in cell growth, proliferation, and differentiation. It codes for the epidermal growth factor receptor, a receptor tyrosine kinase that plays a significant role in stimulating cell growth and division in response to the binding of epidermal growth factor (EGF). Mutations in the EGFR gene can lead to uncontrolled cell growth and are commonly found in lung, colon, and breast cancers. Targeting the EGFR gene and its protein product has become a key strategy in the treatment of these cancers, with drugs like gefitinib and erlotinib specifically inhibiting the activity of the mutated EGFR protein.

The Ba/F3 cell line is a human hematopoietic cell line that is derived from a Burkitt lymphoma. This cell line has been widely used in research for studying the function and regulation of receptor tyrosine kinases, including the EGFR. The Ba/F3 cells have been engineered to express various mutated forms of the EGFR gene, allowing researchers to investigate the effects of these mutations on cell growth, survival, and signal transduction. The Ba/F3 cell line has been instrumental in identifying and characterizing EGFR mutations found in human cancers, contributing to the development of targeted therapies that specifically inhibit the mutated EGFR.

Cancers with epidermal growth factor receptor (EGFR) mutations are difficult to treat owing to acquired resistance to targeted therapy. The C797S mutation makes cancers resistant to osimertinib, a third-generation EGFR TKI. A novel family of EGFR TKIs generated from the marine alkaloid lamellarin N was studied, especially lamellarin 14. This compound demonstrated effectiveness against the C797S mutant, showcasing its potential to overcome resistance associated with existing therapies. In studies, Ba/F3 cells expressing triple-mutant EGFR showed sensitivity to lamellarin 14, indicating its promise in targeted cancer treatment.

Figure 1 describes the effects of lamellarin 14 on the viability of Ba/F3 cells expressing various EGFR mutations, comparing its efficacy to osimertinib under different conditions, including the presence or absence of IL-3. (doi: 10.1111/cas.14839) Figure 1. The researchers established Ba/F3 cells expressing TKI-resistant mutant EGFRs, specifically del ex19/T790M and del ex19/T790M/C797S, to assess the effects of lamellarin 14. (Nishiya N, et al., 2021)

Creative Biogene's Human EGFR Stable Cell Line-Ba/F3 is particularly relevant in this context. This cell line is designed to facilitate the study of EGFR mutations and evaluate the efficacy of novel inhibitors like lamellarin 14. It enables researchers to analyze drug responses in a controlled environment, promoting insights into resistance mechanisms and therapeutic efficacy.

The epidermal growth factor receptor (EGFR) gene is a key factor in cell growth, survival and division. The epidermal growth factor receptor protein is a receptor tyrosine kinase that mediates signalling pathways upon binding to epidermal growth factor (EGF) and other growth factors. Abnormalities in the EGF receptor gene can lead to sustained activation of the EGF receptor protein, which is commonly associated with the development of various types of cancers, including lung, colon, and breast cancers.

Targeting the epidermal growth factor receptor gene product has emerged as an important strategy for the treatment of epidermal growth factor receptor-positive cancers. The development of targeted therapies such as monoclonal antibodies that specifically bind to EGFR proteins (e.g., cetuximab and panitumumab) and small-molecule inhibitors that block the activity of EGFR proteins (e.g., erlotinib and gefitinib) has greatly improved the prognosis of patients with EGFR-positive cancers.

In addition to their role in cancer therapy, epidermal growth factor receptor gene products are important biomarkers for predicting prognosis and guiding the treatment of patients with various types of cancer. For example, mutations or overexpression of the epidermal growth factor receptor gene can be used to identify patients who are more likely to benefit from targeted therapies.

In summary, the epidermal growth factor receptor gene product is a key regulator of cell growth and survival, and its aberrations have been associated with the development of various types of cancer. Targeting the epidermal growth factor receptor gene product has emerged as an important strategy for the treatment and management of epidermal growth factor receptor-positive cancers, improving patient prognosis and providing valuable biomarkers for prognostic and therapeutic guidance.

Customer Q&As

What is the EGFR gene and its role in cancer?

A: The EGFR (Epidermal Growth Factor Receptor) gene encodes a protein that is a key player in cell growth, proliferation, and survival. EGFR is overexpressed or mutated in various cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, and glioblastoma. These alterations lead to uncontrolled cell growth and can drive tumor progression and metastasis.

How does EGFR contribute to cancer development and progression?

A: EGFR contributes to cancer development and progression by activating signaling pathways that promote cell growth, invasion, and angiogenesis. When overexpressed or mutated, EGFR can become constitutively active, leading to unregulated cell proliferation and resistance to apoptosis. This dysregulation can disrupt normal tissue architecture and facilitate the spread of cancer.

Are there any therapeutic implications of targeting the EGFR gene?

A: Targeting the EGFR gene and its protein product is a central strategy in the treatment of certain cancers. Targeted therapies, such as monoclonal antibodies (e.g., cetuximab) and tyrosine kinase inhibitors (e.g., erlotinib), can block the function of EGFR, slowing or stopping the progression of cancer. These treatments are particularly effective in EGFR-positive cancers.

How is the expression of the EGFR gene regulated in normal and cancerous cells?

A: The expression of the EGFR gene is regulated by various factors, including growth factors, cytokines, and transcription factors. In normal cells, EGFR expression is tightly controlled. However, in cancerous cells, EGFR can become overexpressed due to genetic alterations or amplification of the EGFR gene, leading to constitutive activation of its signaling pathways and uncontrolled cell growth.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

Name

Country *

Email *

Customer Reviews

Reputation of the supplier

The supplier of the Human EGFR Stable Cell Line-Ba/F3 has a strong reputation in the industry for providing high-quality cell lines and excellent customer service. Researchers can trust that they are receiving a reliable product that meets their experimental needs.

Germany

2023-08-01

Product standardization

The Human EGFR Stable Cell Line-Ba/F3 is produced under strict standardization protocols, ensuring consistency and reproducibility across different batches of the cell line. This standardization is crucial for researchers to obtain reliable and comparable results.

Germany

2020-12-27

Customization services

The supplier offers customization services for the Human EGFR Stable Cell Line-Ba/F3, allowing researchers to modify the cell line to better suit their specific experimental requirements. This flexibility enables researchers to explore novel research questions and optimize their experimental designs.

Germany

2021-06-19

Technical support

The supplier provides excellent technical support to assist researchers in working with the Human EGFR Stable Cell Line-Ba/F3. This support includes guidance on cell culture techniques, experimental design, and data analysis.

Canada

2020-02-08

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *

Name

Country *

Email *

Related Products

Cat.No.	Product Name	Price
CSC-RO0352	Human MET-Del14-D1228A Stable Cell Line - Ba/F3	Inquiry
CSC-RO0316	Human EGFR-V769-D770_ins_GE Stable Cell Line - Ba/F3	Inquiry
CSC-RO0431	Human METex14Del Stable Cell Line - Ba/F3	Inquiry
CSC-RO0673	Human MERTK Stable Cell Line - THP-1	Inquiry
CSC-RO0746	Human NRAS-G12C Stable Cell Line - Ba/F3	Inquiry
CSC-RO0761	Human KRAS-G12R Stable Cell Line - Ba/F3	Inquiry
CSC-RO0322	Human EGFR-Y764-V765_ins_HH Stable Cell Line - Ba/F3	Inquiry
CSC-RO0392	Human FLT3-D835F Stable Cell Line - Ba/F3	Inquiry
CSC-RO0348	Human KIT-D816Y Stable Cell Line - Ba/F3	Inquiry
CSC-RO0317	Human EGFR-K745-E746_ins_IPVAIK Stable Cell Line - Ba/F3	Inquiry

Human EGFR Stable Cell Line-Ba/F3

Cell Line Information

Cell Culture Information

Safety and Packaging

Gene Information

Documents

Background

Case Study

Applications

Q & A

Customer Reviews

What is the EGFR gene and its role in cancer?

How does EGFR contribute to cancer development and progression?

Are there any therapeutic implications of targeting the EGFR gene?

How is the expression of the EGFR gene regulated in normal and cancerous cells?

Reputation of the supplier

Product standardization

Customization services

Technical support

Related Products

Related Services